Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease.
Saved in:
| Title: | Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. |
|---|---|
| Authors: | Ray GL; Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; x_ray82@hotmail.com (G.L.R.); baidook@mail.nih.gov (K.E.B.); lkeller8@hotmail.com (L.M.M.K.); martinwb@mail.nih.gov (M.W.B.)., Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE |
| Source: | Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2011 Dec 22; Vol. 5 (1), pp. 1-15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Print Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
